SERA
$2.01
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States.
Intraday
Recent News
Sera Prognostics Inc (SERA) Q4 2025: Everything You Need To Know Ahead Of Earnings
This article first appeared on GuruFocus. Sera Prognostics Inc (NASDAQ:SERA) is set to release its Q4 2025 earnings on Mar 18, 2026. The consensus estimate for Q4 2025 revenue is $0.03 million, and the earnings are expected to come in at -$0.19 per share.
The Joint Corp. (JYNT) Beats Q4 Earnings and Revenue Estimates
The Joint (JYNT) delivered earnings and revenue surprises of +33.33% and +10.59%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
LifeMD (LFMD) delivered earnings and revenue surprises of -300.00% and +5.92%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
With 40% ownership, Sera Prognostics, Inc. (NASDAQ:SERA) has piqued the interest of institutional investors
Key Insights Given the large stake in the stock by institutions, Sera Prognostics' stock price might be vulnerable to...
Sera Prognostics (SERA) Upgraded to Buy: Here's Why
Sera Prognostics (SERA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.